PT  - JOURNAL ARTICLE
AU  - Shattock, Andrew J.
AU  - Le Rutte, Epke A.
AU  - Dünner, Robert P.
AU  - Sen, Swapnoleena
AU  - Kelly, Sherrie L.
AU  - Chitnis, Nakul
AU  - Penny, Melissa A.
TI  - Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland
AID  - 10.1101/2021.04.14.21255503
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.14.21255503
4099  - http://medrxiv.org/content/early/2021/04/20/2021.04.14.21255503.short
4100  - http://medrxiv.org/content/early/2021/04/20/2021.04.14.21255503.full
AB  - As vaccination coverage against SARS-CoV-2 increases amidst the emergence and spread of more infectious and potentially more deadly viral variants, decisions on timing and extent of relaxing effective, but unsustainable, non-pharmaceutical interventions (NPIs) need to be made. An individual- based transmission model of SARS-CoV-2 dynamics, OpenCOVID, was developed to compare the impact of various vaccination and NPI strategies on the COVID-19 epidemic in Switzerland. We estimate that any relaxation of NPIs in March 2021 will lead to increasing cases, hospitalisations, and deaths resulting in a ‘third wave’ in spring and into summer 2021. However, we find a cautious phased relaxation can substantially reduce population-level morbidity and mortality. We find that faster vaccination campaign can offset the size of such a wave, allowing more flexibility for NPI to be relaxed sooner. Our sensitivity analysis revealed that model results are particularly sensitive to the infectiousness of variant B.1.1.7.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the Botnar Research Centre for Child Health (to MAP) and the Swiss National Science Foundation NRP 78 Covid-19 2020 (4078P0_198428). MAP is funded by a Swiss National Science Foundation Professorship (PP00P3_17070).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe model code is open source and available here: https://github.com/SwissTPH/OpenCOVID Epidemiological data and demographic data informing the models was obtained from publically available sources https://github.com/SwissTPH/OpenCOVID